News and Trends 31 May 2016
UK Immunotherapy against Grass Allergies moves on to Phase III Trials
Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients. Circassia is based in Oxford (UK) and was part of 2014’s record Biotech IPOs – raising a whopping €268M. It focuses on respiratory diseases, such as asthma and allergies. Its […]